NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6372.00 10.50 (0.17%)

38.06% Gain from 52W Low

369 NSE Volume

NSE 04 Aug, 2025 9:07 AM (IST)

169,156.6

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Divi's Laboratories Ltd. is on 06 Aug 2025 for the purpose of Quarterly Results See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

30 May 2016

6372.00

0.17%

Divis Lab Q4FY16 Update 30May2016

Neutral: Divi's Laboratories Ltd.

Target

Phillip Capital

8 Its proposed greenfield facility with an investment of Rs 5bn in the Kakinada SEZ got delayed as the company is yet get the final control of the targeted land. Divis is currentlyundergoingasettlementprocesswithvillagers(earlierownersoftheland)....

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6727.9

Divi's Laboratories Ltd.

09 Feb 2016

6372.00

0.17%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

08 Feb 2016

6372.00

0.17%

DivisLab 8Feb2016

Neutral: Divi's Laboratories Ltd.

Target

Phillip Capital

8 Delay in shipments both in generics as well as customsynthesis operation inorderto meet justintime supply policy of customers resulted in 9%/11% below expected revenues/PATinQ3.Q4toseespillovereffect....

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

03 Nov 2015, 12:00AM

6372.00

0.17%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

ICICI Securities Limited

Divi's Laboratories Ltd. has gained 27.66% in the last 1 Year

Divi's Laboratories Ltd.

02 Nov 2015

6372.00

0.17%

Divis Laboratories: Q2FY16 Result Review-Margins Outperform (Nov 02, 2015)

Sell: Divi's Laboratories Ltd.

Karvy

Divis Lab Total revenues are up by 15.8% YoY to Rs 9.6 bn lower than our expectation of Rs 10 bn for the quarter. Operating margins stood at 39% in line with our estimate of 38.2% on account of lower overheads.

Divi's Laboratories Ltd. has gained 27.66% in the last 1 Year

Divi's Laboratories Ltd.

02 Nov 2015

6372.00

0.17%

Divislab 2Nov2015

Neutral: Divi's Laboratories Ltd.

Phillip Capital

Outlook and valuation: While earnings were higher than we expected, H1 performance is almost in line with our FY16 expectations. Hence, we have maintained our estimates for FY16/17 and continue to value the company at Rs 1045 (22x FY17 earnings), implying 9%...

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6727.9

Divi's Laboratories Ltd.

31 Oct 2015

6372.00

0.17%

Divis Laboratories - 2QFY16 Result Update

Hold: Divi's Laboratories Ltd.

Reliance Securities

Divi's Labs delivered an in-line 2Q. Sales (up 15.9% yoy), margins (38.8%, up 230bps yoy) and profitability (Rs2.8bn, up 26.1% yoy) were in-line as Generic API and Custom Synthesis proffered ramp up. The company has reiterated its sales guidance at 15-20% and operating margins yoy at ~37-38% for FY16E in-line with our assumptions. With capacity expansion targeting higher volumes and sustenance of base business growth we believe that long-term outlook is encouraging, remaining undeterred by quarterly lumpiness. Besides, favorable currency could surprise us positively. However, backed...

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6727.9

Divi's Laboratories Ltd.

10 Aug 2015

6372.00

0.17%

Divis Laboratories: Q1FY16 Result Review - Generics business Outperforms (Aug 10, 2015)

Hold: Divi's Laboratories Ltd.

Karvy

Divi's Lab Total revenues are up by 25.8% YoY to Rs 8.1 bn higher than our expectation of Rs 7.7 bn for the quarter. Operating margins stood at 37.1% lower than our estimate of 39.1% on account of lower gross margins due to product mix. Net Profit was up by 44.8% YoY to Rs 2,432 mn (higher than our estimates of Rs 2,123 mn) aided by higher other income and lower depreciation.

Divi's Laboratories Ltd. is trading above its 200 day SMA of 6091.3

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf